[go: up one dir, main page]

ATE229072T1 - Für den vorläufer des für die tumorabstossung verantwortlichen antigens mage-3 kodierendes, isoliertes nukleinsäuremolekül und seine verwendung - Google Patents

Für den vorläufer des für die tumorabstossung verantwortlichen antigens mage-3 kodierendes, isoliertes nukleinsäuremolekül und seine verwendung

Info

Publication number
ATE229072T1
ATE229072T1 AT94912246T AT94912246T ATE229072T1 AT E229072 T1 ATE229072 T1 AT E229072T1 AT 94912246 T AT94912246 T AT 94912246T AT 94912246 T AT94912246 T AT 94912246T AT E229072 T1 ATE229072 T1 AT E229072T1
Authority
AT
Austria
Prior art keywords
nucleic acid
acid molecule
precursor
responsible
tumor rejection
Prior art date
Application number
AT94912246T
Other languages
English (en)
Inventor
Beatrice Gaugler
Den Eynde Benoit Van
Thierry Boon-Falleur
Der Bruggen Pierre Van
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE229072T1 publication Critical patent/ATE229072T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Casings For Electric Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT94912246T 1993-03-26 1994-03-17 Für den vorläufer des für die tumorabstossung verantwortlichen antigens mage-3 kodierendes, isoliertes nukleinsäuremolekül und seine verwendung ATE229072T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/037,230 US6235525B1 (en) 1991-05-23 1993-03-26 Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
PCT/US1994/002877 WO1994023031A1 (en) 1993-03-26 1994-03-17 Isolated nucleic acid molecules coding for tumor rejection antigen precursor mage-3 and uses thereof

Publications (1)

Publication Number Publication Date
ATE229072T1 true ATE229072T1 (de) 2002-12-15

Family

ID=21893179

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94912246T ATE229072T1 (de) 1993-03-26 1994-03-17 Für den vorläufer des für die tumorabstossung verantwortlichen antigens mage-3 kodierendes, isoliertes nukleinsäuremolekül und seine verwendung

Country Status (15)

Country Link
US (6) US6235525B1 (de)
EP (1) EP0690915B1 (de)
JP (1) JP3594307B2 (de)
KR (1) KR100288749B1 (de)
CN (1) CN1110556C (de)
AT (1) ATE229072T1 (de)
AU (1) AU685790B2 (de)
CA (1) CA2159098C (de)
DE (1) DE69431834T2 (de)
FI (1) FI954536A7 (de)
NO (1) NO953699L (de)
NZ (1) NZ263693A (de)
TW (1) TW432111B (de)
WO (1) WO1994023031A1 (de)
ZA (1) ZA941644B (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925729A (en) * 1991-05-23 1999-07-20 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
USRE40089E1 (en) * 1991-05-23 2008-02-19 Ludwig Institute For Cancer Research Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor
US6060257A (en) * 1994-06-03 2000-05-09 Ludwig Institute For Cancer Research Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
AU7440196A (en) * 1995-10-12 1997-04-30 Chiron Corporation Baboon mage-3 homologs, dna encoding the homologs, and a process for their use
UY24367A1 (es) * 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
FR2746110B1 (fr) * 1996-03-14 1998-04-17 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
SI1659179T1 (sl) 1998-02-05 2011-10-28 Glaxosmithkline Biolog Sa S tumorjem povezani antigenski derivati iz MAGE druĹľine in zaporedja nukleinskih kislin, ki jih kodirajo, uporabni za pripravo fuzijskih proteinov in sestavkov za cepljenje
US6446109B2 (en) * 1998-06-29 2002-09-03 Sun Microsystems, Inc. Application computing environment
US20080318889A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7960540B2 (en) * 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
EP1181304B1 (de) 1999-04-08 2007-10-10 Antisoma Research Limited Antiproliferative aktivität von g-reichen oligonukleotiden und verfahren um sie zur bindung an nukleotin zu verwenden
US20080318890A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) * 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
IT1312568B1 (it) * 1999-05-21 2002-04-22 Genera Spa Peptidi immunogenici e loro uso.
AU1013701A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Modified gp100 and uses thereof
JP3603138B2 (ja) * 2000-02-18 2004-12-22 独立行政法人理化学研究所 細胞死抑制タンパク質
AU2001258102B2 (en) 2000-05-10 2007-03-01 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
JP2004501648A (ja) * 2000-06-26 2004-01-22 グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム チオレドキシンおよび目的のポリペプチドの間に融合するユビキチンを含む三重融合タンパク質
JP4541645B2 (ja) 2001-04-12 2010-09-08 インペリアル・イノベイションズ・リミテッド Ｉ型癌の診断および治療
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
ATE517122T1 (de) 2002-04-09 2011-08-15 Sanofi Pasteur Ltd Modifizierte cea-nukleinsäure und entsprechende expressionsvektoren
US20040223949A1 (en) * 2002-10-22 2004-11-11 Sunnybrook And Women's College Health Sciences Center Aventis Pasteur, Ltd. Vaccines using high-dose cytokines
EP1670926B1 (de) * 2003-10-08 2011-04-20 Sanofi Pasteur Limited Modifizierter cea/b7-vektor
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US20070154889A1 (en) * 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy
SG187482A1 (en) 2007-11-07 2013-02-28 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
US20090131351A1 (en) * 2007-11-16 2009-05-21 Antisoma Research Limited Methods, compositions, and kits for modulating tumor cell proliferation
CN102202687B (zh) 2008-03-14 2015-07-29 赛诺菲巴斯德生物制剂有限责任公司 复制缺陷型黄病毒疫苗和疫苗载体
EP3165540A1 (de) 2010-04-13 2017-05-10 Celldex Therapeutics, Inc. Antikörper zur bindung von humanem cd27 und verwendungen davon
PL3892295T3 (pl) 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US10155031B2 (en) 2012-11-28 2018-12-18 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
ES2901705T3 (es) 2014-06-06 2022-03-23 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos
US10564165B2 (en) 2014-09-10 2020-02-18 Genentech, Inc. Identification of immunogenic mutant peptides using genomic, transcriptomic and proteomic information
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016094309A1 (en) 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
EP3268037B1 (de) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
PL3303396T3 (pl) 2015-05-29 2023-03-06 Bristol-Myers Squibb Company Przeciwciała przeciwko ox40 i ich zastosowanie
AU2016291817A1 (en) 2015-07-16 2018-02-22 Biolinerx Ltd. Compositions and methods for treating cancer
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
EP3445783A2 (de) 2016-04-18 2019-02-27 Celldex Therapeutics, Inc. Agonistische antikörper zur bindung von humanem cd40 und verwendungen davon
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
WO2018127919A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A SIRP1 alpha-41BBL FUSION PROTEIN AND METHODS OF USE THEREOF
DK3565579T3 (da) 2017-01-05 2023-09-04 Kahr Medical Ltd Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
IL250916A0 (en) 2017-03-02 2017-06-29 Geiger Benjamin Methods for growing t cells in culture and their use
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
US20210187023A1 (en) 2017-06-27 2021-06-24 The Trustees Of Princeton University Compositions And Methods For Enhancing Immunotherapy
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
US12397036B2 (en) 2018-01-26 2025-08-26 Cambridge Enterprise Limited Peptide exchange protein
WO2020012486A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
US12329816B2 (en) 2018-08-24 2025-06-17 The Trustees Of Princeton University Immunotherapy with metabolic enzyme expression
GB201820444D0 (en) 2018-12-14 2019-01-30 Adaptimmune Ltd Marker for T cell expansion
CA3146248A1 (en) 2019-07-11 2021-01-14 Kahr Medical Ltd. Heterodimers and methods of use thereof
GB201911954D0 (en) 2019-08-20 2019-10-02 Adaptimmune Ltd Lentiviral transduction methods
US20230048719A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
WO2021137230A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells and uses of same
CN111647066B (zh) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 Wt1多肽肿瘤抑制剂
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
KR20230126727A (ko) 2020-12-30 2023-08-30 이뮤노믹 쎄라퓨틱스, 인크. 항-hvem 항체
GB202303250D0 (en) 2023-03-06 2023-04-19 King S College London Method and compounds
WO2025155971A1 (en) 2024-01-19 2025-07-24 Immunomic Therapeutics, Inc Anti-activin receptor 1c (alk-7) receptor antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61104788A (ja) * 1984-10-26 1986-05-23 Teijin Ltd 核酸塩基配列
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
JPH05246889A (ja) * 1992-03-05 1993-09-24 Seitai Chiyousetsu Kenkyusho:Kk 制癌方法および制癌剤
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof

Also Published As

Publication number Publication date
AU6447594A (en) 1994-10-24
NO953699D0 (no) 1995-09-20
FI954536A0 (fi) 1995-09-25
AU685790B2 (en) 1998-01-29
DE69431834T2 (de) 2003-09-18
EP0690915B1 (de) 2002-12-04
US6946289B1 (en) 2005-09-20
NZ263693A (en) 1996-07-26
EP0690915A1 (de) 1996-01-10
WO1994023031A1 (en) 1994-10-13
US6599699B1 (en) 2003-07-29
US6565857B1 (en) 2003-05-20
KR100288749B1 (ko) 2001-05-02
US6025474A (en) 2000-02-15
DE69431834D1 (de) 2003-01-16
FI954536L (fi) 1995-09-25
CA2159098C (en) 2003-04-29
JP3594307B2 (ja) 2004-11-24
EP0690915A4 (de) 1997-11-12
ZA941644B (en) 1994-10-12
CN1110556C (zh) 2003-06-04
CN1093751A (zh) 1994-10-19
JPH08508402A (ja) 1996-09-10
US6235525B1 (en) 2001-05-22
TW432111B (en) 2001-05-01
CA2159098A1 (en) 1994-10-13
FI954536A7 (fi) 1995-09-25
NO953699L (no) 1995-11-20
US6552180B1 (en) 2003-04-22

Similar Documents

Publication Publication Date Title
ATE229072T1 (de) Für den vorläufer des für die tumorabstossung verantwortlichen antigens mage-3 kodierendes, isoliertes nukleinsäuremolekül und seine verwendung
EP0783511A4 (de) Isoliertes nukleinsäuremolekül, das für den tumorabstossungs-antigenvorläufer dage kodiert und seine verwendung
DE69617440D1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
FI956019A0 (fi) Eristettyjä peptidejä, jotka muodostavat komplekseja MHC-molekyyli HLA-C-klooni-10:n kanssa, ja niiden käyttö
HUP0103758A2 (hu) Neurotróf faktorok
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
ATE165980T1 (de) Nukleinsaürefragmente, die mannose bindende fragmente vom menschlichen mannosebindenden protein kodieren
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
ATE234858T1 (de) Isolierte und verkürzte nukleinsäuremoleküle kodierend für gage-tumorabstossungsantigen
NZ332369A (en) Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof
ATE313551T1 (de) Isoliertes nukleinsäuremolekül, das die tumorabstossungs-antigenvorläufer mage- c1 und mage-c2 kodiert und seine verwendung
ATE166656T1 (de) Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen
GEP20043386B (en) β -Amyloid Peptide-Binding Proteins and Polynucleotides Encoding the Same
GR3034725T3 (en) Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy.
WO1996009391A3 (en) Dna sequence and protein of the non-structural reading frame i of the human parvovirus b19
ATE490979T1 (de) Neueskollagen-ähnliches protein clac, dessen vorläufer und dafür kodierende gene
UA66753C2 (en) Immunostimulator and method for its production
DE3850933D1 (de) Anticoagulatorisches Protein PP4-X, seine Herstellung und Verwendung.
EP0446797A3 (en) Synthetic peptides containing factor viia sequences and their use
TW372973B (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
DE60208040D1 (de) Anti-ssrp-1 monoklonale antikörper und hybridome zur deren herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0690915

Country of ref document: EP